Century Therapeutics, Inc. (NASDAQ:IPSC – Get a rating) principal shareholder Versant Venture Capital Vi, L. sold 550,000 shares of the company in a transaction dated Tuesday, August 9. The shares were sold at an average price of $13.03, for a total value of $7,166,500.00. Following the transaction, the insider now directly owns 11,816,814 shares of the company, valued at $153,973,086.42. The sale was disclosed in an SEC filing, available at this link. Large shareholders who own at least 10% of a company’s stock are required to disclose their sales and purchases to the SEC.
Century Therapeutics Price Performance
CISP opened at $12.15 on Friday. The company has a debt ratio of 0.03, a quick ratio of 16.62 and a current ratio of 16.62. Century Therapeutics, Inc. has a 52-week low of $7.32 and a 52-week high of $32.90. The stock has a market capitalization of $715.03 million, a PE ratio of -3.67 and a beta of 0.34. The stock’s 50-day moving average price is $9.72 and its 200-day moving average price is $10.98.
Therapeutic Century (NASDAQ:IPSC – Get a rating) last released its results on Monday, May 16. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.21). The company posted revenue of $1.06 million in the quarter, compared to $20.00 million expected by analysts. On average, equity research analysts expect Century Therapeutics, Inc. to post -2.32 EPS for the current year.
Hedge funds weigh on Century Therapeutics
Several hedge funds have recently changed their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Century Therapeutics during the fourth quarter, valued at approximately $246,000. The New York State Common Retirement Fund increased its position in Century Therapeutics shares by 267.5% during the fourth quarter. The New York State Common Retirement Fund now owns 7,718 shares of the company valued at $122,000 after buying 5,618 additional shares in the last quarter. Royce & Associates LP purchased a new stake in shares of Century Therapeutics during the fourth quarter valued at approximately $205,000. ProShare Advisors LLC purchased a new stake in shares of Century Therapeutics during the fourth quarter worth approximately $163,000. Finally, HarbourVest Partners LLC purchased a new equity stake in Century Therapeutics during the fourth quarter valued at approximately $232,000. 57.50% of the shares are held by hedge funds and other institutional investors.
Analysts set new price targets
A number of stock analysts have commented on IPSC shares. HC Wainwright began coverage of Century Therapeutics in a research note on Monday, May 23. They issued a “buy” rating and a price target of $27.00 on the stock. Piper Sandler cut her price target on Century Therapeutics from $38.00 to $22.00 and set an “overweight” rating on the stock in a Monday, May 16 research note. Roth Capital began coverage of Century Therapeutics in a research note on Friday, June 10. They issued a “buy” rating on the stock. Finally, William Blair began coverage of Century Therapeutics in a research note on Thursday, May 12. They issued a “market performance” rating on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating for the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.00.
Century Therapeutics Company Profile
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumors and hematological malignancies. The Company’s lead product candidate is CNTY-101, an allogeneic cell therapy derived from induced pluripotent stem cells (iPSC) and chimeric antigen receptor (CAR)-iNK targeting CD19 for relapsed and refractory B-cell lymphoma.
Get news and reviews for Century Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Century Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.